4. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J ClinOncol 2006;24:1057-63.
5. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71.
6. Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 2017;18:1116-25.
7. Kies MS, Mira JG, Crowley JJ, et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. J ClinOncol 1987;5:592-600.
Hsueh, W. T., Su, W. C., Chen, F. F., & Chen, H. H. W. (2005). 非肺部小細胞癌的放射治療經驗. 放射治療與腫瘤學, 12(2), 93-101. https://doi.org/10.6316/TRO/200512(2)93
Chiu, S. C., Chang, K. H., Chen, Y. J., Chung, C. H., Lai, Y. L., & Wu, M. H. (1998). 胸腔放射治療無法提昇晚期非小細胞肺癌之存活率. 放射治療與腫瘤學, 5(4), 277-283. https://doi.org/10.6316/TRO/199805(4)277